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ABSTRACT
Introduction Prevalence rates of breastfeeding remain 
low even though the World Health Organization (WHO) and 
the American Academy of Pediatrics recommend exclusive 
breast feeding for the first 6 months of life in combination 
with appropriate complementary feeding beyond six 6 
months of age. There have been several studies that 
address the implication of drinking animal milk and/or 
infant formula on children’s health and development when 
breast feeding is not offered during the first year of life. 
Vast improvements have been made in infant formula 
design, which may increase its benefits compared with 
animal’s milk. The objective of this review is therefore to 
synthesise the most recent evidence on the effects of the 
consumption of animal milk compared with infant formula 
in non- breastfed or mixed breastfed infants aged 6–11 
months.
Methods and analysis We will conduct a systematic 
review and meta- analysis of studies that assessed the 
effect of animal milk compared with formula or mixed- fed 
(breastmilk and formula) on infants aged 6–11 months. 
The primary outcomes of interest include anaemia, 
gastrointestinal blood loss, weight for age, height for 
age and weight for height. We will include randomised 
and non- randomised studies with a control group. We 
will use the Cochrane risk of bias tools to assess the 
risk of bias. We will use meta- analysis to pool findings 
if the identified studies are conceptually homogenous 
and data are available from more than one study. We will 
assess the overall quality of evidence using the Grading 
of Recommendations Assessment, Development, and 
Evaluation approach.
Ethics and dissemination This is a systematic review, 
so no patients will be directly involved in the design 
or development of this study. The findings from this 
systematic review will be disseminated to relevant patient 
populations and caregivers and will guide the WHO’s 
recommendations on formula consumption versus animal 
milk in infants aged 6–11 months.
Trial registration number CRD42020210925.
INTRODUCTION
The World Health Organization (WHO) and 
the American Academy of Pediatrics recom-
mend exclusive breastfeeding for the first 6 
months of life and continuation of breast-
feeding beyond 6 months in combination 
with appropriate complementary feedings 
for up to 2 years or beyond.1 2 However, prev-
alence rates of breastfeeding still remain 
low in many contexts, with many infants still 
being given formula milk or cow’s milk before 
or after 6 months of age.3 4 Use of cow’s milk 
in infancy has been associated with gastroin-
testinal blood loss, iron deficiency anaemia 
and increased solute load for kidneys.5–8 The 
composition of cow’s milk is vastly different 
from that of breastmilk and infant formula, 
which is manufactured to mimic breastmilk.9 
Cow’s milk has a high amount of protein 
(3.4 g/100 mL vs 0.7–1.4100 mL in breast-
milk),10 and the composition of the protein 
is different—50%–80% of breastmilk is 
comprised of whey protein versus only 18% 
for cow’s milk.9 Ingesting a large amount of 
protein in the first year of life has been asso-
ciated with childhood obesity.6 9 Unmodi-
fied goat’s milk also contains high amounts 
Strengths and limitations of this study
 ► We will search several databases for relevant lit-
erature and will included randomised and non- 
randomised studies.
 ► We will assess risk- of- bias for each outcome and 
use the Grading of Recommendations Assessment, 
Development, and Evaluation to assess the overall 
quality of evidence.
 ► We will conduct subgroup analysis for age group (7 
months vs 9 months), country, type of feeding (non- 
breastfed versus mixed fed) and type of animal milk.
 ► We will conduct meta- analyses if data are available 
from more than one study, and if there is clinical and 
methodological homogeneity in the included studies.
 ► All the included studies may not report the data for 
infants 6–11 months of age which will be a limita-
tion of the study.
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of protein and mineral content and low folate content. 
Goat’s milk does not appear to have any clear nutritional 
advantage over cow’s milk and is not less allergenic.11 
There have been several studies that have examined 
the implications of drinking animal milk and/or infant 
formula on children’s health and development.5 7 12–17 
The past two decades have also yielded vast improvements 
in the design of infant formulas, which may increase the 
benefits of infant formula over animal milk.18 The objec-
tive of the proposed review is, therefore, to synthesise the 
most recent research on the effects of the consumption 
of animal milk compared with infant formula in non- 
breastfed or mixed breastfed infants aged 6–11 months 
of age.
Objective
For non- breastfed or mixed- fed (breastmilk and formula) 
infants 6–11 months of age, is the consumption of animal 
milk compared with infant formula, associated with bene-
ficial or adverse outcomes for health and development?
METHODS AND ANALYSIS
Study type
We will include individual and cluster randomised 
trials. We will also include quasi- randomised experi-
mental design studies, defined as those that attempted 
to randomly allocate participants to conditions but the 
method of randomisation was not truly random.19 For 
instance, an example of a quasi- randomised design is 
an experimental study where the randomisation was 
attempted but the methods of sequence generation were 
inadequate such as randomisation based on date of birth 
of participants or date of enrolment in the study etc. 
We will also include cohort studies, defined as a study 
on a group of participants based on certain criteria (eg, 
geography, age and so on) but none of the participants 
have the outcome of interest at the time of recruitment 
and develop outcomes over time in relation to expo-
sure versus no exposure to a risk factor. A cohort study 
could be prospective or retrospective.19 We will exclude 
case control studies, case series, case reports and cross- 
sectional studies. All analyses will be conducted and 
reported separately for randomised and non- randomised 
studies.
Population
We will include studies that included apparently healthy 
infants 6–11 months of age who were non- breastfed 
or mixed fed (breastmilk and formula) irrespective of 
gestational age and birth weight. We will include studies 
that started animal milk feeding between 4 months and 
11 months of age. If a study includes participants who 
began intervention before 4 months of age but includes 
participants older than 4 months of age as well, we will 
consider that study eligible if more than half (50%) of 
the study participants meet the inclusion criteria (ie, 
4–11 months of age). We will include studies where 
participants are diagnosed with HIV or have had HIV 
exposure. We will exclude studies if participants are diag-
nosed with AIDS. We will exclude studies that focused 
on breastfed infants only without other types of milk 
provided. We will exclude studies with participants 
who have chronic diseases such as bronchopulmonary 
dysplasia, genetic disorders, aerodigestive problems or 
congenital anomalies.
Intervention
We will include studies that assessed the effect of animal 
milk in infants 6–11 months of age. The animal milk 
could be cow milk, goat milk or camel milk. We will 
include studies in which animal milk was the main milk 
drink as defined by study authors or more than 50% of 
the infant’s milk intake was animal milk. We will include 
studies irrespective if the animal milk was boiled or not 
boiled, pasteurised or unpasteurised, or if the animal 
milk was full- fat, reduced fat or skim milk. We will exclude 
studies that used plant- based milk such as rice milk, pea 
milk, coconut milk or almond milk.
Comparison
The comparison group in the included studies will be 
formula feeding or mixed feeding (ie, breast feeding and 
formula feeding). We will include studies irrespective of 
the type of formula used; namely, this could include cow’s 
milk- based formula, partially or extensively hydrolysed 
formula or plant- based formulas such as soy formula. 
The Federal Food, Drug, and Cosmetic Act defines infant 
formula as ‘a food which purports to be or is represented 
for special dietary use solely as a food for infants by 
reason of its simulation of human milk or its suitability as 
a complete or partial substitute for human milk’.20
Outcomes
Primary outcomes
 ► Anaemia (dichotomous outcome, as defined by 
authors) at 7 months, 9 months, 12 months and the 
longest follow- up.
 ► Gastrointestinal blood loss (dichotomous outcome 
based on stool occult testing) at 7 months, 9 months, 
12 months and the longest follow- up.
 ► Weight for age (kg or Z scores) at 7 months, 9 months, 
12 months and the longest follow- up.
 ► Height for age (cm or Z scores) at 7 months, 9 months, 
12 months and the longest follow- up.
 ► Weight for height Z score at 7 months, 9 months, 
12 months and the longest follow- up.
Secondary outcomes
 ► Iron deficiency anaemia (dichotomous outcome) 
at 7 months, 9 months, 12 months and the longest 
follow- up.
 ► Blood iron level (continuous outcome) at 7 months, 9 
months, 12 months and the longest follow- up.
 ► Blood ferritin level (continuous outcome) at 7 months, 
9 months, 12 months and the longest follow- up.
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 ► Haemoglobin concentration in the stool (continuous 
outcome) at 7 months, 9 months, 12 months and the 
longest follow- up.
 ► Haemoglobin concentration in the serum (contin-
uous outcome) at 7 months, 9 months, 12 months and 
the longest follow- up.
 ► Fatty acid status (continuous outcome) at 7 months, 9 
months, 12 months and longest follow- up.
 ► Gut health: Diarrhoea (>3 loose stools per day) 
(dichotomous outcome) at 7 months, 9 months, 12 
months and the longest follow- up.
 ► Gut health: Constipation (<3 bowel movements 
per week) (dichotomous outcome) at 7 months, 9 
months, 12 months and longest follow- up.
 ► Pneumonia (as defined by authors) (dichotomous 
outcome) at 7 months, 9 months, 12 months and the 
longest follow- up.
 ► Allergy (IgE- mediated and non- IgE- mediated and 
mixed) (dichotomous outcome) at 7 months, 
9 months, 12 months and the longest follow- up.
We will include both immunoglobulin E (IgE)- 
mediated, non- IgE- mediated and mixed milk allergies. 
IgE- mediated allergies can be identified with a skin prick 
test or blood test for specific IgE and symptoms typically 
arise immediately after ingesting the milk product. Non- 
IgE- mediated allergies will not be identified with a skin 
prick test or blood test and symptoms typically arise 48 
hours after ingestion of milk product.21 Non- IgE- mediated 
allergies can be identified using allergen elimination and 
standard challenge procedure in which the allergen is 
removed from the diet for up to 2 weeks and then reintro-
duced to determine if symptoms are elicited.22
 ► Obesity (dichotomous outcome) at 1 year and longest 
follow- up.
Obesity is defined as a body mass index (BMI) at or 
above the 95th percentile for children and teens of 
the same age and sex.23 It can also be defined as BMI 
for age Z scores >3 for children under 5 years of age.
 ► Overweight (dichotomous outcome) at 1 year and the 
longest follow- up.
Overweight is defined as a BMI at or above the 85th 
percentile and below the 95th percentile for children 
and teens of the same age and sex.23 It can also be 
defined as BMI for age Z scores >2 for children under 
5 years of age.
 ► Neurodevelopmental outcomes (continuous 
outcome) at 1 year and the longest follow- up.
The term neurodevelopment is a composite term 
that refers to cognitive, neurological and/or sensory 
outcomes. This may include intellectual disability as 
measured on the Mental Developmental Index of the 
Bayley Scales of Infant Development, gross motor de-
lay measured on Gross Motor Function Classification 
System and so on.
If a study does not report outcomes at 7 months but 
instead reports outcomes at 6 months or 8 months, it will 
be included with outcomes at 7 months. Similarly, if a 
study does not report outcomes at 9 months but instead 
reports outcomes at 10 months, it will be included with 
outcomes at 9 months. If a study does not report outcomes 
at 12 months, but instead reports those outcomes at 11, 
13 or 14 months, it will be included with outcomes at 
12 months.
Literature search
We will conduct systematic electronic searches on multiple 
databases, including PubMed, EMBASE, the Cochrane 
Central Register for Controlled Trials, Web of Science, 
CINHAL, Scopus, WHO Global Index Medicus. There 
will be no restrictions applied to the searches based on 
outcomes, study design, publication status, publication 
date or language. A proposed search strategy for PubMed 
is shown in online supplemental appendix 1. We will 
search  ClinicalTrials. gov to identify ongoing studies. We 
will also search the websites of relevant international agen-
cies, such as the WHO (including WHO’s Reproductive 
Health Library), UNICEF, Global Alliance for Improved 
Nutrition, International Food Policy Research Institute, 
International Initiative for Impact Evaluation (3ie), 
Nutrition International, World Bank, USAID and affili-
ates (eg, FANTA, SPRING) and the World Food Program. 
The reference sections of previously published reviews 
and the latest published studies will also be searched for 
potentially eligible studies.
Data extraction and synthesis
Selection of studies
Searches from all the databases will be combined in 
bibliographic software (EndNote) and duplicates will be 
removed. Two authors (AI and JC or AI and JME) will first 
screen the titles to identify potentially eligible studies; any 
studies retained at this step will proceed to the second 
stage of screening for a full- text review; finally, any studies 
deemed eligible during the full- text review will proceed 
to the third step of full data extraction. Any conflict will 
be resolved by discussion and with the help of the senior 
author on the team if needed. We will use coding soft-
ware (Covidence) to conduct the screening.24 If a study is 
only available in abstract form, we will write to authors to 
obtain details on methods and results. If a study is avail-
able in a language other than English, we will attempt to 
have the translation completed using the local resources. 
If a study was published in more than one report (multiple 
publications), we will count those multiple reports as a 
single study and extract information from all the available 
reports as needed.
Data extraction
A data extraction sheet will be designed and piloted for 
the extraction of information from the selected studies 
(online supplemental file 2). Two authors (JME and 
JC) will independently extract the data and compare 
their findings. Any conflict will be resolved by discussion 
and with the help of the senior author on the team if 
needed. We will extract the information on type of study 
(randomised control trial, quasirandomised experimental 
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design or cohort study) study site, study year, study popu-
lation (age, nutritional status, per cent women), methods 
for data collection and analysis, intervention (dose, dura-
tion, frequency), age of outcome assessment, compar-
ison, outcomes, whether the results were adjusted for 
confounders, what confounders were considered (socio-
economic status, maternal employment, maternal age, 
maternal level of education, age- appropriate comple-
mentary feeding) and risk of bias (online supplemental 
document).
Assessment of risk of bias in included studies
Study risk of bias will be assessed using the Cochrane risk 
of bias tool (ROB 2.0)25 for randomised controlled trials 
and using the Cochrane risk of bias in non- randomised 
studies (ROBINS- I) tool for non- randomised studies of 
interventions.26 Two review authors will independently 
evaluate and agree on the risk of bias for the individual 
studies for an outcome. Any disagreements will be 
resolved by discussion and if no agreement can be made, 
the senior review author will be consulted. We will assess 
the effect of assignment to intervention (the intention- 
to- treat effect) by addressing five domains of signalling 
questions including: bias arising from the randomisation 
process, bias due to deviations from intended interven-
tions, bias due to missing outcome data, bias in measure-
ment of the outcome and bias in selection of the reported 
result. Each domain will get a ranking of low risk of bias, 
some concerns of bias or high risk of bias. We will include 
quotes from the study for each signalling question as 
evidence for our ranking decision. The overall risk of 
bias will be determined based on the worst ranking for 
individual domains. For example, if only one domain is 
ranked ‘some concerns’, then the overall risk of bias will 
be ‘some concerns’.
DATA SYNTHESIS
We will develop a Preferred Reporting Items for System-
atic Reviews and Meta- Analyses (PRISMA) flow diagram 
based on the search strategy and eligibility assessment to 
show the flow of included and excluded studies.27 We will 
analyse the randomised and non- randomised studies sepa-
rately. We will report findings from all included studies in 
a narrative synthesis and will also conduct meta- analyses 
to synthesise evidence across studies quantitatively. Meta- 
analyses will be conducted when data are available from 
more than one study, and when there is clinical and meth-
odological homogeneity in the included studies. Dichoto-
mous outcomes will be measured using relative risk effect 
sizes and will be reported with their corresponding 95% 
CIs. Continuous outcomes will be measured using mean 
difference effect sizes and will also be reported along 
with their 95% CIs. We will use the generic inverse vari-
ance weighting method for meta- analysis. We will use the 
random effects model for meta- analysis given that there 
might be heterogeneity in effects due to variability in the 
study populations and interventions used. We will use 
RevMan28 and Stata29 software for the statistical analysis.
In the case of morbidity outcomes, we will combine 
all available data whenever possible if outcomes are 
measured in different ways. For example, we will include 
all types of diarrhoea (mild, moderate and severe) as a 
dichotomous value (yes/no) if participants had greater 
than 3 instances of loose stools per day. We will include 
occurrence of anaemia, gastrointestinal blood loss based 
on stool occult testing, iron deficiency anaemia, pneu-
monia and allergies (non- IgE, IgE- mediated) throughout 
the study as dichotomous values (yes/no). For dichot-
omous outcomes, we will extract the total number of 
participants in each group and the number of partici-
pants experiencing an event. We will pool the dichoto-
mous outcomes in a meta- analysis to obtain a summary 
estimate in the form of relative risk and report it with 
its corresponding 95% CI. We will include haemoglobin 
concentration in stool, weight for age, height for age and 
weight for height as continuous values. For continuous 
outcomes, we will pool the data to obtain a pool mean 
difference and report it with its 95% CI. In the event that 
data are reported in different units (eg, few studies report 
weight in kg and the others report in Z scores), we will use 
a standardised mean difference effect size and report it 
with its 95% CI.
Unit of analysis issues
Multiple-arm trial
Studies with multiple treatment arms will be included if 
eligible. For multiple- arm trials, we will include data in a 
way that the only difference between the groups is use of 
animal milk.
Cluster trials
Cluster assignment trials will be analysed together with 
individual randomised trials. We will use the cluster 
adjusted values; if the trial results are not adjusted for 
cluster design, we will adjust the result by methods given 
in the Cochrane handbook for systematic reviews.19
STUDIES WITH MISSING DATA
We will document attrition during data extraction. If the 
authors report the missing data and report the imputa-
tions for the missing data, we will use the latter. If data 
are missing for some cases, or if reasons for dropout are 
not reported, we will contact the trial authors to request 
the full data. In the event that a study does not report the 
SD for the continuous outcome, we will write to authors 
to request the data. If the SD data are not available from 
authors, we will use SD from a similar study that has similar 
study population. We will prefer to use the final values of 
a continuous outcome for a given follow- up. If the final 
values are not available but the difference between the 
end and the start of the study, we will write to authors to 
request the final values. If the final values are not avail-
able, we will use the difference or rate of change.
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Assessment of heterogeneity
Assessment of heterogeneity in meta- analysis determines how 
different the included studies are from each other. Clinical 
heterogeneity refers to differences in patient population or 
treatment whereas methodological heterogeneity refers to 
differences in how the study was designed. Statistical hetero-
geneity refers to large differences in the outcome (outside 
of chance) that may be due to clinical or methodological 
heterogeneity.30 Statistical heterogeneity will be assessed 
using Tau,2 χ2 and I2 statistics. We will assess statistical hetero-
geneity by visual inspection of forest plots, by performing 
the χ² test (assessing the p value) and by calculating the Tau2 
and I2 statistic. Statistical heterogeneity will be considered 
substantial if the p value is less than 0.10, I2 value exceeds 
50% and inspection of forest plots show substantial variability 
in the effect of the intervention. We will perform subgroup 
analysis to determine the reasons for any identified statistical 
heterogeneity.
Assessment of reporting bias
Small study and publication bias will be assessed using 
funnel plots and regression tests for funnel plot asym-
metry when the meta- analysis includes at least ten studies.
Subgroup analysis and investigation of heterogeneity
 ► Age group: 7 months vs 9 months.
If a study does not begin intervention at 7 months but 
instead at 6 months or 8 months, it will be included 
in the 7 months age subgroup. Similarly, if a study 
does not begin intervention at 9 months but instead 
at 10 months, it will be included with outcomes at 
9 months.
 ► Country: Low- income and middle- income country 
versus high- income country.
 ► Type of feeding: non- breastfeeding versus mixed 
feeding.
 ► Type of animal milk: Cow, goat, buffalo, camel, sheep.
We will test the subgroups difference by using χ² test.
SENSITIVITY ANALYSIS
 ► Studies with a high overall risk of bias excluded.
 ► Random versus fixed effect meta- analysis model.
Rating of overall quality of evidence
We will assess the overall quality of evidence for the effect 
of the intervention on each primary outcome using the 
Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) using the software GradePro.31 
The GRADE approach entails identifying and assessing 
many different features that affect the certainty of evidence 
in the review, including type of study design, statistical 
heterogeneity, directness of evidence, within- study risk of 
bias, risk of publication bias and precision of effect esti-
mates.32 We will consider evidence from randomised trials 
as high quality and downgrade the evidence one level for 
serious limitations (table 1).
We will rate the overall quality of the body of evidence 
as very low (we have very little confidence in the effect esti-
mate), low (we have limited confidence in the effect esti-
mate), moderate (we have moderate confidence in the 
effect estimate; the true effect is likely close to the estimate 
of the effect) or high (we have high confidence that the true 
effect lies close to that of the estimate of the effect). We will 
present the results of the GRADE assessment in the form of a 
summary of findings tables for the primary outcomes.
AMENDMENTS
We will do the literature searches, screening of titles, selec-
tion of studies, data extraction and analysis according to 
a priori plan described in this protocol. If we do any addi-
tional analysis or change any of the a priori strategies, we 
will clearly describe that in the methods section.
Patient and public involvement
No patient or public involvement was considered in 
preparation of this protocol.
Consent for publication
Authors give consent for publication of this review.
Availability of data and materials
We will keep all the data available for review by the editors 
and peer reviewers and will provide raw data for the 
general public on request.
Table 1 GRADE method for rating the quality of evidence
Study design
Quality of 
evidence Lower if Higher if
Randomised 
trial
High Risk of bias Large effect
−1 Serious +1 Serious
−2 Very serious +2 Very serious
Inconsistency   Dose response
−1 Serious +1 Evidence of a 
gradient
−2 Very serious All plausible 
confounding
Indirectness +1 Would reduce 
a demonstrated 
effect or
−1 Serious +1 Would suggest 
a spurious effect 
when results 
show no effect
−2 Very serious   
Imprecision   
−1 Serious   




Moderate Publication bias   
  Low −1 Serious   
  Very low −2 Very serious   copyright.
 on M
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ETHICS AND DISSEMINATION
This is a systematic review and there will be no direct 
contact with the patients. The findings from this system-
atic review will be disseminated to relevant patient 
populations and caregivers as they will be used to guide 
recommendations through the WHO on whether the use 
of infant formula is better than animal’s milk in infants 
aged 6–11 months.
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